NCT02982707View on ClinicalTrials.gov

Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

September 28, 2018

Study Completion Date

September 28, 2018

Conditions
Thrombosis
Interventions
DRUG

BMS-986177

Single oral dose

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Miami

78215

Texas Liver Institute, San Antonio

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY